{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:32:10Z","timestamp":1791325930768,"version":"4.3.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T00:00:00Z","timestamp":1456444800000},"content-version":"vor","delay-in-days":390,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.cell.2015.01.042","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T12:01:00Z","timestamp":1424952060000},"page":"977-989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":352,"title":["Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy"],"prefix":"10.1016","volume":"160","author":[{"given":"Joan","family":"Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher\u00a0A.","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph\u00a0D.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oph\u00e9lia","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Ercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil\u00a0S.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross\u00a0S.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi\u00a0A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip\u00a0C.","family":"Amrein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cichowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Letai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2015.01.042_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cell.2015.01.042_bib2","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1182\/blood-2009-10-251082","article-title":"Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K\/Akt\/mTOR-addicted lymphomas","volume":"115","author":"Bhatt","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cell.2015.01.042_bib3","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.2011.36.0354","article-title":"American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays","volume":"29","author":"Burstein","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cell.2015.01.042_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2015.01.042_bib5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2015.01.042_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cell.2015.01.042_bib7","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.01.042_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2015.01.042_bib9","doi-asserted-by":"crossref","first-page":"11867","DOI":"10.1158\/0008-5472.CAN-07-1961","article-title":"Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion","volume":"67","author":"Deng","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2015.01.042_bib10","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2015.01.042_bib11","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/onc.2009.526","article-title":"Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor","volume":"29","author":"Ercan","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.cell.2015.01.042_bib12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"Ercan","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cell.2015.01.042_bib13","doi-asserted-by":"crossref","first-page":"19503","DOI":"10.1073\/pnas.0905056106","article-title":"Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition","volume":"106","author":"Faber","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2015.01.042_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/2159-8290.CD-11-0106","article-title":"BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors","volume":"1","author":"Faber","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cell.2015.01.042_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Garraway","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cell.2015.01.042_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature12831","article-title":"Inconsistency in large pharmacogenomic studies","volume":"504","author":"Haibe-Kains","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cell.2015.01.042_bib17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cell.2015.01.042_bib18","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2015.01.042_bib19","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.275.5303.1132","article-title":"The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis","volume":"275","author":"Kluck","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.01.042_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood-2007-10-119438","article-title":"Functional proteomic profiling of AML predicts response and survival","volume":"113","author":"Kornblau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cell.2015.01.042_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","article-title":"Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics","volume":"2","author":"Letai","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2015.01.042_bib22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","article-title":"Elucidating distinct roles for NF1 in melanomagenesis","volume":"3","author":"Maertens","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cell.2015.01.042_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.01.042_bib24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.01.042_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.cell.2015.01.042_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ymeth.2013.04.006","article-title":"BH3 profiling in whole cells by fluorimeter or FACS","volume":"61","author":"Ryan","year":"2013","journal-title":"Methods"},{"key":"10.1016\/j.cell.2015.01.042_bib27","doi-asserted-by":"crossref","first-page":"12895","DOI":"10.1073\/pnas.0914878107","article-title":"Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes","volume":"107","author":"Ryan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2015.01.042_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molcel.2013.08.048","article-title":"BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response","volume":"51","author":"Sarosiek","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cell.2015.01.042_bib29","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2015.01.042_bib30","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature06913","article-title":"The cancer biomarker problem","volume":"452","author":"Sawyers","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cell.2015.01.042_bib31","doi-asserted-by":"crossref","first-page":"34ps27","DOI":"10.1126\/scitranslmed.3001087","article-title":"Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials","volume":"2","author":"Sikorski","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2015.01.042_bib32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.cell.2015.01.042_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1059108","article-title":"Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death","volume":"292","author":"Wei","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.01.042_bib34","doi-asserted-by":"crossref","first-page":"pe13","DOI":"10.1126\/scisignal.2003684","article-title":"The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment","volume":"6","author":"Yaffe","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cell.2015.01.042_bib35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867415001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867415001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T16:58:21Z","timestamp":1537808301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867415001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0092867415001208"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2015.01.042","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725369660.793525483","asserted-by":"object"}]},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2015.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}